Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.4
2.4
Journals
JCDD
Special Issues
Cardiaovascular Gene Therapy
share announcement

Cardiaovascular Gene Therapy

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425).

Deadline for manuscript submissions: closed (1 June 2019) | Viewed by 12932

Special Issue Editor

Dr. Kiyotake Ishikawa

E-Mail Website
Guest Editor
Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Interests: cardiac gene therapy; heart failure; translational research; large animal experiment; cardiac physiology; LV unloading
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Advances in vector technologies and our expanding knowledge in molecular biology render gene therapy as a new attractive approach to improve the growing burden of cardiovascular diseases throughout the world. Gene delivery vectors and methods with efficient, target specific, and safe profile are essential to promote clinical translation. In this Special Issue of JCDD “Cardiaovascular Gene Therapy”, the journal is seeking original manuscripts, comprehensive reviews and method protocols of novel techniques related to cardiovascular gene therapy.

Dr. Kiyotake Ishikawa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Over-expression
  • Gene scilencing
  • Gene editing
  • Vectors
  • Cardiac targeting
  • Cardiovascular disease
  • Pulmonary hypertension

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 1641 KiB  
Review
Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer
by Michael G. Katz, Anthony S. Fargnoli, Sarah M. Gubara, Kenneth Fish, Thomas Weber, Charles R. Bridges, Roger J. Hajjar and Kiyotake Ishikawa
J. Cardiovasc. Dev. Dis. 2019, 6(1), 8; https://0-doi-org.brum.beds.ac.uk/10.3390/jcdd6010008 - 15 Feb 2019
Cited by 23 | Viewed by 5715
Abstract
Advances in DNA- and RNA-based technologies have made gene therapy suitable for many lung diseases, especially those that are hereditary. The main objective of gene therapy is to deliver an adequate amount of gene construct to the intended target cell, achieve stable transduction [...] Read more.
Advances in DNA- and RNA-based technologies have made gene therapy suitable for many lung diseases, especially those that are hereditary. The main objective of gene therapy is to deliver an adequate amount of gene construct to the intended target cell, achieve stable transduction in target cells, and to produce a clinically therapeutic effect. This review focuses on the cellular organization in the normal lung and how gene therapy targets the specific cell types that are affected by pulmonary disorders caused by genetic mutations. Furthermore, it examines the pulmonary barriers that can compromise the absorption and transduction of viral vectors and genetic agents by the lung. Finally, it discusses the advantages and limitations of direct intra-tracheal gene delivery with different viral vectors in small and large animal models and in clinical trials. Full article
(This article belongs to the Special Issue Cardiaovascular Gene Therapy)
►▼ Show Figures

Figure 1

17 pages, 653 KiB  
Review
Gene Therapy Approaches to Biological Pacemakers
by Melad Farraha, Saurabh Kumar, James Chong, Hee Cheol Cho and Eddy Kizana
J. Cardiovasc. Dev. Dis. 2018, 5(4), 50; https://0-doi-org.brum.beds.ac.uk/10.3390/jcdd5040050 - 19 Oct 2018
Cited by 8 | Viewed by 6631
Abstract
Bradycardia arising from pacemaker dysfunction can be debilitating and life threatening. Electronic pacemakers serve as effective treatment options for pacemaker dysfunction. They however present their own limitations and complications. This has motivated research into discovering more effective and innovative ways to treat pacemaker [...] Read more.
Bradycardia arising from pacemaker dysfunction can be debilitating and life threatening. Electronic pacemakers serve as effective treatment options for pacemaker dysfunction. They however present their own limitations and complications. This has motivated research into discovering more effective and innovative ways to treat pacemaker dysfunction. Gene therapy is being explored for its potential to treat various cardiac conditions including cardiac arrhythmias. Gene transfer vectors with increasing transduction efficiency and biosafety have been developed and trialed for cardiovascular disease treatment. With an improved understanding of the molecular mechanisms driving pacemaker development, several gene therapy targets have been identified to generate the phenotypic changes required to correct pacemaker dysfunction. This review will discuss the gene therapy vectors in use today along with methods for their delivery. Furthermore, it will evaluate several gene therapy strategies attempting to restore biological pacing, having the potential to emerge as viable therapies for pacemaker dysfunction. Full article
(This article belongs to the Special Issue Cardiaovascular Gene Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop